Zentalis Pharmaceuticals Inc
NASDAQ:ZNTL
Zentalis Pharmaceuticals Inc
NASDAQ:ZNTL
Price:
2.75
USD
-7.09%
Market Closed
Market Cap:
$198.7m
Income Statement
Earnings Waterfall
Zentalis Pharmaceuticals Inc
Zentalis Pharmaceuticals Inc
Income Statement
Zentalis Pharmaceuticals Inc
Zentalis Pharmaceuticals Inc
Currency: USD
| Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
41
N/A
|
41
N/A
|
41
N/A
|
67
+66%
|
27
-60%
|
27
N/A
|
27
N/A
|
|
| Operating Income | ||||||||||||||||||||||
| Operating Expenses |
(79)
|
(119)
|
(153)
|
(181)
|
(200)
|
(208)
|
(172)
|
(181)
|
(224)
|
(227)
|
(229)
|
(270)
|
(278)
|
(249)
|
(300)
|
(261)
|
(249)
|
(255)
|
(226)
|
(197)
|
(180)
|
|
| Selling, General & Administrative |
(23)
|
(34)
|
(43)
|
(43)
|
(42)
|
(41)
|
(41)
|
(50)
|
(53)
|
(55)
|
(54)
|
(50)
|
(54)
|
(59)
|
(64)
|
(65)
|
(64)
|
(87)
|
(83)
|
(74)
|
(70)
|
|
| Research & Development |
(55)
|
(85)
|
(110)
|
(137)
|
(158)
|
(167)
|
(175)
|
(174)
|
(171)
|
(173)
|
(175)
|
(220)
|
(224)
|
(190)
|
(236)
|
(196)
|
(186)
|
(168)
|
(144)
|
(124)
|
(110)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
43
|
43
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Operating Income |
(79)
N/A
|
(119)
-51%
|
(153)
-29%
|
(181)
-18%
|
(200)
-11%
|
(208)
-4%
|
(172)
+17%
|
(181)
-5%
|
(224)
-24%
|
(227)
-2%
|
(229)
-1%
|
(270)
-18%
|
(278)
-3%
|
(249)
+11%
|
(259)
-4%
|
(220)
+15%
|
(209)
+5%
|
(187)
+10%
|
(199)
-6%
|
(170)
+15%
|
(153)
+10%
|
|
| Pre-Tax Income | ||||||||||||||||||||||
| Interest Income Expense |
0
|
1
|
1
|
1
|
1
|
0
|
1
|
1
|
3
|
6
|
10
|
14
|
19
|
23
|
53
|
26
|
30
|
26
|
(12)
|
20
|
16
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
43
|
43
|
0
|
0
|
0
|
0
|
(5)
|
(5)
|
(5)
|
(51)
|
0
|
0
|
0
|
(4)
|
(13)
|
(13)
|
(13)
|
|
| Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
| Total Other Income |
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Pre-Tax Income |
(78)
N/A
|
(118)
-51%
|
(152)
-29%
|
(180)
-18%
|
(156)
+13%
|
(165)
-5%
|
(172)
-4%
|
(180)
-5%
|
(221)
-23%
|
(221)
0%
|
(225)
-2%
|
(261)
-16%
|
(264)
-1%
|
(277)
-5%
|
(206)
+26%
|
(194)
+6%
|
(179)
+8%
|
(166)
+7%
|
(224)
-35%
|
(163)
+27%
|
(150)
+8%
|
|
| Net Income | ||||||||||||||||||||||
| Tax Provision |
(0)
|
(0)
|
(1)
|
(1)
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
1
|
1
|
1
|
1
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
|
| Income from Continuing Operations |
(78)
|
(119)
|
(153)
|
(181)
|
(156)
|
(164)
|
(171)
|
(179)
|
(221)
|
(221)
|
(224)
|
(260)
|
(264)
|
(276)
|
(205)
|
(194)
|
(179)
|
(166)
|
(223)
|
(162)
|
(149)
|
|
| Income to Minority Interest |
1
|
1
|
1
|
1
|
7
|
7
|
7
|
7
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Equity Earnings Affiliates |
0
|
0
|
0
|
0
|
0
|
(2)
|
(4)
|
(9)
|
(11)
|
(16)
|
(17)
|
(25)
|
(23)
|
(16)
|
(14)
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Net Income (Common) |
(78)
N/A
|
(118)
-52%
|
(152)
-29%
|
(179)
-18%
|
(149)
+17%
|
(159)
-7%
|
(168)
-6%
|
(182)
-8%
|
(232)
-28%
|
(237)
-2%
|
(241)
-2%
|
(285)
-18%
|
(286)
0%
|
(292)
-2%
|
(219)
+25%
|
(194)
+11%
|
(179)
+8%
|
(166)
+7%
|
(223)
-35%
|
(162)
+27%
|
(149)
+8%
|
|
| EPS (Diluted) |
-2.06
N/A
|
-4.19
-103%
|
-3.75
+11%
|
-4.4
-17%
|
-3.33
+24%
|
-3.72
-12%
|
-3.71
+0%
|
-3.55
+4%
|
-4.08
-15%
|
-4.48
-10%
|
-4.06
+9%
|
-4.69
-16%
|
-4.05
+14%
|
-4.47
-10%
|
-3.07
+31%
|
-2.75
+10%
|
-2.52
+8%
|
-2.33
+8%
|
-3.11
-33%
|
-2.25
+28%
|
-2.06
+8%
|
|
Switch to:
Switch to:
See Also
Discover More
